Research Progress of γδT Cells in Tumor Immunotherapy.
| Autor: | Li Y; Department of Clinical Laboratory, The First Affiliated Hospital of Kunming Medical University, Kunming, China.; Yunnan Key Laboratory of Laboratory Medicine, Kunming, China., Mo XP; Department of Clinical Laboratory, The First Affiliated Hospital of Kunming Medical University, Kunming, China.; Yunnan Key Laboratory of Laboratory Medicine, Kunming, China., Yao H; Cancer Biotherapy Center, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, China., Xiong QX; Department of Clinical Laboratory, The First Affiliated Hospital of Kunming Medical University, Kunming, China.; Yunnan Key Laboratory of Laboratory Medicine, Kunming, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer control : journal of the Moffitt Cancer Center [Cancer Control] 2024 Jan-Dec; Vol. 31, pp. 10732748241284863. |
| DOI: | 10.1177/10732748241284863 |
| Abstrakt: | Background: γδT cells are special innate lymphoid cells, which are not restricted by major histocompatibility complex (MHC). γδT cells mainly exist in human epidermis and mucosal epithelium. They can secrete a variety of cytokines and chemokines involved in immune regulation, and produce effective cytotoxic responses to cancer cells. Purpose: To investigate the role of γδT cells in tumor immunotherapy, to understand its anti-tumor mechanism, and to explore the synergistic effect with other treatment modalities. This therapy is expected to become an important means of cancer treatment. Research Design: In this review presents a comprehensive analysis of the existing literature, focusing on the efficacy of γδT cells in a variety of tumor types. Results: The mechanism of γδT cells recognizing tumor antigens and killing tumor was clarified. The tumor immunotherapy based on γδT cells and its application in clinical practice were summarized. Conclusions: γδT cells have shown promising potential in tumor immunotherapy, but the therapeutic effect varies according to the type of tumor, and some patients have poor response. There are still some challenges in the treatment of this disease, such as non-standard expansion regimens and different responses of patients, indicating that the existing treatment methods are not complete. Future research should focus on perfecting γδT cell expansion protocols, gaining a deeper understanding of its anti-tumor mechanisms, and exploring synergies with other treatment modalities. This multifaceted study will promote the development of γδT cells in the field of cancer immunotherapy. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|